{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"PFS time was measured from the date of randomization until the first radiographic documentation of progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of first dose, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.","groups":[{"description":"Participants received 10 mg dose of LY3435151 via intravenous (IV) as an IV push or IV bolus infusion.","id":"OG000","title":"10 mg LY3435151"}],"populationDescription":"Zero participants were analyzed. The study was terminated early and no data was collected.","reportingStatus":"POSTED","timeFrame":"Baseline to Objective Progression or Death Due to Any Cause (Up to 4 Months)","title":"Progression Free Survival (PFS)","type":"SECONDARY"}